基于IHC技术平台的肿瘤伴随诊断产品

Search documents
艾德生物2025年中报简析:营收净利润同比双双增长,公司应收账款体量较大
Zheng Quan Zhi Xing· 2025-07-29 22:59
Core Insights - The company reported a total revenue of 579 million yuan for the first half of 2025, representing a year-on-year increase of 6.69% [1] - The net profit attributable to shareholders reached 189 million yuan, up 31.41% year-on-year [1] - The gross profit margin was 84.0%, a slight decrease of 1.35% compared to the previous year, while the net profit margin increased by 23.17% to 32.63% [1] Financial Performance - Total revenue for 2024 was 543 million yuan, while for 2025 it was 579 million yuan, showing a growth of 6.69% [1] - Net profit for 2024 was 144 million yuan, increasing to 189 million yuan in 2025, marking a growth of 31.41% [1] - The company’s operating cash flow per share increased by 24.78% to 0.44 yuan [1] Accounts Receivable and Liabilities - Accounts receivable amounted to 597 million yuan, which is 234.1% of the net profit, indicating a significant level of receivables [1][4] - Interest-bearing liabilities increased by 27.72% to 68.42 million yuan [1] Cost Management - Total selling, administrative, and financial expenses were 169 million yuan, accounting for 29.1% of revenue, a decrease of 18.61% year-on-year [1] - Financial expenses saw a significant reduction of 135.9% due to increased exchange gains [3] Investment and Market Position - The company’s return on invested capital (ROIC) was 12.55%, indicating strong capital returns [3] - The company has a robust product offering with a focus on domestic alternatives for imported products, particularly in tumor companion diagnostics [5] Fund Holdings - Major funds holding the company’s shares include 招商核心优选股票A and 工银专精特新混合A, with significant increases in holdings [5]